Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Breda – page 42

1 243 clinical trials in Breda, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Breda at a glance
1 243
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 243 trials in Breda

Open in trial search

Rheumatoid arthritis

Not yet recruiting

Optimizing biologic tapering in patients with rheumatoid arthritis using tocilizumab, drug combination, and olfactory placebo conditioning

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Universiteit Leiden

Long‑term study of Pompe disease in all patients receiving alglucosidase alfa drug combination (miglustat, cipaglucosidase alfa, avalglucosidase alfa)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alglucosidase Alfa
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Acute myeloid leukaemia

Not yet recruiting

A Phase 1/2 study of CHM-029 alone and in combination drug regimen in adults with newly diagnosed, relapsed or refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Charm Therapeutics Limited

Semaglutide, Glucose and Glucagon for Prevention of Post‑transplantation Diabetes Mellitus in Kidney Transplant Recipients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Glucagon
  • Sponsor:Radboud universitair medisch centrum Stichting

Endometrial cancer

Not yet recruiting

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:GSK5733584
  • Sponsor:Glaxosmithkline Research & Development Limited

Hypertrophic cardiomyopathy

Not yet recruiting

Study of aficamten and 68Ga‑FAPI‑46 versus placebo in asymptomatic obstructive hypertrophic cardiomyopathy patients

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Aficamten
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Deupirfenidone
  • Sponsor:Celea Therapeutics Inc.

Choroid melanoma

Not yet recruiting

Long‑Term Follow‑Up Study of Belzupacap Sarotalocan in Patients with Early Choroidal Melanoma

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Aura Biosciences Inc.

Epcoritamab plus rituximab versus rituximab alone in elderly, frail or unfit patients with newly diagnosed diffuse large B‑cell lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Epcoritamab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Durvalumab after chemoradiation for patients with limited‑stage small cell lung cancer: a randomized trial of high‑dose versus standard thoracic radiation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Gastric cancer+1

Not yet recruiting

Capecitabine drug combination in perioperative treatment for patients with gastric and esophageal cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Pleural mesothelioma

Not yet recruiting

Reducing Toxicity of Dual PD‑1 and CTLA‑4 Checkpoint Therapy in Pleural Mesothelioma Patients with Ustekinumab (anti‑p40)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ustekinumab
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Breda

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple myeloma, breast cancer, and leukemia treatments. Studies evaluate novel drug combinations and targeted therapies to improve patient outcomes.

  • Advanced/Metastatic Breast Cancer Treatment
  • Novel Therapies for AML
  • Melanoma Treatment Optimization

Investigations include combination therapies and treatment discontinuation strategies for various cancer types.

02 Cardiovascular Studies

Research focusing on coronary artery disease and post-procedural care, including innovative diagnostic techniques and antithrombotic strategies.

  • Advanced Imaging Technologies
  • Post-TAVI Treatment Protocols
  • Stroke Prevention Strategies

Emphasis on personalized treatment approaches and diagnostic accuracy improvement.

03 Respiratory Medicine

Clinical trials examining respiratory infections and chronic conditions, including vaccine development and asthma management strategies.

  • RSV Vaccine Studies
  • Asthma Treatment Innovation
  • Lung Cancer Therapies

Focus on both preventive measures and treatment optimizations for respiratory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.